These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 33896337)

  • 1. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
    Li H; Fang Y; Guo S; Yang Z
    Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
    [No Abstract]   [Full Text] [Related]  

  • 2. GPR119 agonists for the treatment of type 2 diabetes.
    Jones RM; Leonard JN; Buzard DJ; Lehmann J
    Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
    Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
    Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GPR40 agonist AS2575959 exhibits glucose metabolism improvement and synergistic effect with sitagliptin on insulin and incretin secretion.
    Tanaka H; Yoshida S; Minoura H; Negoro K; Shimaya A; Shimokawa T; Shibasaki M
    Life Sci; 2014 Jan; 94(2):115-21. PubMed ID: 24269216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPR119 agonists 2009-2011.
    Buzard DJ; Lehmann J; Han S; Jones RM
    Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
    Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
    Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
    Matsumoto K; Yoshitomi T; Shimada T
    Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
    Dhayal S; Morgan NG
    Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening for GPR119 modulators identifies a novel compound with anti-diabetic efficacy in db/db mice.
    Zhang M; Feng Y; Wang J; Zhao J; Li T; He M; Yang D; Nosjean O; Boutin J; Renard P; Wang MW
    PLoS One; 2013; 8(5):e63861. PubMed ID: 23704946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics, pharmacodynamics, and toxicity of novel small-molecule GPR119 agonists to treat type-2 diabetes and obesity.
    Patil M; Casari I; Thapa D; Warne LN; Dallerba E; Massi M; Carlessi R; Falasca M
    Biomed Pharmacother; 2024 Aug; 177():117077. PubMed ID: 38968799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and characterization of novel small molecule agonists of G protein-coupled receptor 119.
    Zhang SY; Li J; Xie X
    Acta Pharmacol Sin; 2014 Apr; 35(4):540-8. PubMed ID: 24681896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
    Shah U
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.